SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

Disaggregation of Revenue

License revenues were comprised of the following for the periods presented:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
	(In thousands)
Paid-up license revenue agreements	$	7,360	$	16,600	$	9,553	$	22,010
Recurring License Revenue Agreements	702		800		1,124		1,193
Total	$	8,062	$	17,400	$	10,677	$	23,203

Printronix's net revenues were comprised of the following for the periods presented:

	Three Months Ended June 30,		Six Months Ended June 30,
	2022		2022
	(In thousands)
Printers, consumables and parts	$	7,876	$	17,514
Services	779		2,033
Total	$	8,655	$	19,547

Schedule of Other Operating Cost and Expense, by Component

Cost of revenues were comprised of the following for the periods presented:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
	(In thousands)
Inventor royalties	$	190	$	448	$	360	$	543
Contingent legal fees	755		4,356		1,304		5,450
Litigation and licensing expenses	1,089		1,837		2,333		4,099
Amortization of patents	2,600		2,612		5,201		4,474
Total	$	4,634	$	9,253	$	9,198	$	14,566

Schedule of Product Warranty Liability

The following is a summary of the accrued warranty liabilities, which are included in accrued expenses and other current liabilities, and other long-term liabilities in the consolidated balance sheets:

	Six Months Ended June 30,
	2022
	(In thousands)
Beginning balance	$	222
Estimated future warranty expense	22
Warranty claims settled	(98)
Ending balance	$	146

Unrealized Gain (Loss) on Investments

Equity securities at fair value for the periods presented were comprised of the following:

Security Type	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
	(In thousands)
June 30, 2022:
Equity securities - Life Sciences Portfolio (Note 3)	$	44,854	$	57,688	$	(463)	$	102,079
Equity securities - other common stock	49,421		2		(25,157)		24,266
Total	$	94,275	$	57,690	$	(25,620)	$	126,345
December 31, 2021:
Equity securities - Life Sciences Portfolio (Note 3)	$	56,037	$	262,811	$	(1,488)	$	317,360
Equity securities - other common stock	43,822		2,068		(1,472)		44,418
Total	$	99,859	$	264,879	$	(2,960)	$	361,778

The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the consolidated statements of operations:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
	(In thousands)
Change in fair value of equity securities of public    companies	$	(32,458)	$	(35,057)	$	(204,098)	$	(29,683)
Change in fair value of equity securities without readily    determinable fair value	—		46,154		—		77,956
Gain on sale of equity securities of public    companies	5,217		15,055		64,705		15,055
Net realized and unrealized (loss) gain	$	(27,241)	$	26,152	$	(139,393)	$	63,328

Schedule of Useful Lives of Property and Equipment

Depreciation and amortization is computed on a straight-line basis over the following estimated useful lives of the assets:

Machinery and equipment	2 to 10 years
Furniture and fixtures	3 to 5 years
Computer hardware and software	3 to 5 years
Leasehold improvements	2 to 5 years (Lesser of lease term or useful life of improvement)